These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7532717)

  • 1. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus.
    Stafford FJ; Fleisher TA; Lee G; Brown M; Strand V; Austin HA; Balow JE; Klippel JH
    J Rheumatol; 1994 Nov; 21(11):2068-70. PubMed ID: 7532717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function.
    Fishwild DM; Strand V
    J Rheumatol; 1994 Apr; 21(4):596-604. PubMed ID: 7518519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate.
    Cannon GW; Marble DA; Griffiths MM; Cole BC; McCall S; Schulman SF; Strand V
    J Rheumatol; 1995 Feb; 22(2):207-13. PubMed ID: 7537827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM; Aberle S; Bernhard SL; Kung AH
    Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
    Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
    Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.
    Skyler JS; Lorenz TJ; Schwartz S; Eisenbarth GS; Einhorn D; Palmer JP; Marks JB; Greenbaum C; Saria EA; Byers V
    J Diabetes Complications; 1993; 7(4):224-32. PubMed ID: 7693056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxin depletion of T cells and its effect on hematopoietic progenitor cells in human cord blood.
    Xu M; Lu S; Shen B; Li Y
    Chin Med J (Engl); 2001 Apr; 114(4):355-9. PubMed ID: 11780453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group.
    Strand V; Lipsky PE; Cannon GW; Calabrese LH; Wiesenhutter C; Cohen SB; Olsen NJ; Lee ML; Lorenz TJ; Nelson B
    Arthritis Rheum; 1993 May; 36(5):620-30. PubMed ID: 7683881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
    Huang W; Sinha J; Newman J; Reddy B; Budhai L; Furie R; Vaishnaw A; Davidson A
    Arthritis Rheum; 2002 Jun; 46(6):1554-62. PubMed ID: 12115186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
    Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.